N-hydroksy-2-(alkyl, aryl eller heteroarylsulfanyl, sulfinyl eller sulfonyl)-3-substituerte alkyl, aryl eller heteroarylamider, anvendelsederav og farmasöytiske preparater inneholdende disse

• Main Authors: GROSU, GEORGE THEODORE, JACOBSON, MARCY PAMELA, DAVIS, JAMIE MARIE, O'DELL, MATHEW JAMES, COLE, DEREK CECIL, VENKATESAN, ARANAPAKAM MUDUMBAI, HU, BAIHUA, BAKER, JANNIE LEA
• Format: Patent
• Language: Norwegian
• Published: 24.02.2003
• Edition: 6
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF- alpha converting enzymes (TACE), a pro-inflammatory cytokine, catalyze the formation of TNF- alpha from membrane-bound TNF- alpha precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF- alpha converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. The compounds of this invention are represented by formula (I), where R , R , R and R are described herein.